TRI Launches TRIAL.OS: A New Operating System for Intelligent Clinical Trials

CAMBRIDGE, England, Oct. 13, 2026 /PRNewswire/ -- TRI, the experts in Risk-Based Quality Management (RBQM), today announced the launch of TRIAL.OS, a new operating system for intelligent clinical trials. TRIAL.OS signals the start of a new era of AI-augmented clinical research, elevating study teams with data insights and driving trial efficiency with dramatically accelerated outcomes. TRIAL.OS democratises value, allowing companies access to a suite of targeted applications, only paying for what they use whether that be as a standalone app, as part of the OPRA RBQM platform, or alongside their existing technologies.

TRIAL.OS poses a previously unasked question: What if your data could talk? What if it could tell you where the risks with your trial are, why, and provide guidance as to what to do about them?

"The OS in TRIAL.OS stands for operating system, and we mean it. If we are going to change an industry we have to change how we work internally, and how we help our customers work." said Duncan Hall, CEO of TRI. "We challenged how we envision, how we develop, how we commercialise and how we allow access to our solutions. We asked what opportunities does AI allow us to capture that we've never been able to before, and we transformed our business to take advantage of those opportunities.  TRIAL.OS moves teams from operational trial management to intelligent trial management. It elevates expert judgment instead of automating it, and that changes how trials get designed, monitored and delivered."

A new model, from protocol to database lock

TRIAL.OS is being built around six functions (understand, predict, explain, recommend, automate and learn) that move teams from signal overload to guided action.

Each app starts with a real problem worth solving, so teams can reach the value they need without paying for technology they do not. RBQM has largely been the preserve of organizations with the budget to commit to a permanent technology platform. TRIAL.OS changes that and brings value within reach of any company running clinical trials, one app at a time.

Organizations can see TRIAL.OS in action with their own protocol or a TRI synthetic protocol matched to their therapy area. One document goes in; structured intelligence comes out.

Built to respond

TRIAL.OS has been developed with customers working alongside TRI, running the apps against their own protocols and shaping what gets built next. TRIAL.OS will ship new capabilities every month. Ideas raised by clients are prototyped in weeks rather than queued for a distant roadmap, then taken through the same validated development process as everything else TRI builds.

Built for regulated studies

TRIAL.OS is developed under the same quality management system as OPRA, in line with ICH E6(R3), 21 CFR Part 11, GCP and GDPR. Every output is a draft that the team reviews and owns, and it is governed by an AI framework covering human oversight and EU AI Act alignment.

Learn more at www.tritrials.com/trial-os

About TRI

TRI has spent 13 years helping sponsors and CROs deliver better-quality clinical trials through Risk-Based Quality Management. More than 500 global clinical trials have run on OPRA, TRI's RBQM platform, and more than half of TRI's people have worked at a sponsor or a CRO before joining.